Medical News

RSS

O2h signs agreement to provide discovery services to Karyopharm Therapeutics

O2h (Ahmedabad, India) is pleased to announce the signing of an agreement with Karyopharm Therapeutics, Inc. (Newton, Massachusetts, USA) under which O2h will provide Karyopharm discovery services to advance Karyopharm's lead small molecule program toward the nomination of a development candidate.

7 Jun 2010

Merck Serono reports long-term follow-up data of cilengitide Phase II study for recurrent glioblastoma

Merck Serono, a division of Merck KGaA, Darmstadt, Germany announced today that long-term follow-up data of a randomized Phase II study of two cilengitide doses in recurrent glioblastoma were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

7 Jun 2010

KMI receives $2.8M grant to support delivery of teletherapy service to stroke survivors in rural areas

Kinetic Muscles, Inc., an innovator in robotic neurotherapy technology, today announced it has received a $2.8 million grant from the National Institute of Neurological Disorder and Stroke of the National Institutes of Health that will support delivery of KMI's revolutionary teletherapy service to stroke survivors in rural areas.

7 Jun 2010

Managing Myeloma launches MTR tool to help practitioners treat patients with multiple myeloma

Managing Myeloma is pleased to announce the launch of the Myeloma Treatment Resource at the annual American Society of Clinical Oncology meeting in Chicago. The MTR, developed by the Managing Myeloma multidisciplinary scientific advisors, is a compilation of convenient, unique tools and resources essential for practitioners treating patients with multiple myeloma.

7 Jun 2010

Simcere Pharmaceutical to increase stake in Jilin Boda

Simcere Pharmaceutical Group, a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced that it has entered into an agreement to acquire an 80% stake in Xiangao Investment Company Ltd, an investment company registered in China, as its sole business, holds a 49% stake in Jilin Boda Pharmaceutical Co. Ltd..

7 Jun 2010

Data shows VB-201 controls inflammatory responses associated with autoimmune diseases, atherosclerosis

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced preclinical data demonstrating that VB-201 regulates inflammatory pathways, suggesting that it may effectively control inflammatory responses associated with autoimmune diseases and atherosclerosis.

7 Jun 2010

Adeona completes 50% enrollment in Part 2 CopperProof-2 study of oral zinc cysteine for Alzheimer's Disease

Adeona Pharmaceuticals, Inc. announced the completion of 50% enrollment in Part 2 of its clinical study, A Prospective, Randomized, Double Blind Trial of a Novel Oral Zinc Cysteine Preparation in Alzheimer's Disease (CopperProof-2).

7 Jun 2010

Immersion signs non-exclusive, worldwide license agreement with Simbionix USA

Immersion Corporation, the leading developer and licensor of haptics technology, and Simbionix USA Corporation, the world's leading provider of simulation and training products for medical professionals and the healthcare industry, today announced that the companies have entered into a new license agreement and have successfully settled litigation that was pending in the United States District Court for the Northern District of Ohio.

7 Jun 2010

GSK submits BENLYSTA MAA for systemic lupus erythematosus

Human Genome Sciences, Inc. today announced that GlaxoSmithKline (GSK) has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for approval to market BENLYSTA® (belimumab) for the treatment of systemic lupus erythematosus (SLE).

7 Jun 2010

Pharmacoeconomic methods influence only 13% of hospital formulary system decisions: Survey

Pharmacoeconomic methods rank low as a decision influencer on formulary changes, according to a new survey released today by the Society of Hospital Medicine and the American Society of Health-System Pharmacists. Respondents reported that only 13 percent of formulary system decisions made by Pharmacy and Therapeutics committees in hospitals is influenced by pharmacoeconomic methods.

7 Jun 2010

Cytheris completes €12 million Series D financing

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that it has completed a €12 million ($15 million) Series D financing.

7 Jun 2010

Millennium reports on data of VELCADE for multiple myeloma from 2010 ASCO oral presentations

Millennium: The Takeda Oncology Company today reported on data from oral presentations of VELCADE® (bortezomib) for Injection based therapy in multiple myeloma presented at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO). These data highlight VELCADE based therapy in both transplant and non-transplant eligible previously untreated multiple myeloma patients, as well as VELCADE used as induction and/or maintenance therapy.

7 Jun 2010

ASHP honors First DataBank pharmacist with the title of Fellow for excellence in pharmacy practice

First DataBank, a leading provider of drug databases that help drive patient safety, today announced that the American Association of Health-System Pharmacists will honor First DataBank pharmacist Joan Kapusnik-Uner, Pharm.D, with the title of "Fellow" in recognition of the excellence she has achieved in pharmacy practice. The 2010 Fellows will be honored on Tuesday, June 8, 2010, during the ASHP Summer Meeting in Tampa, FL.

7 Jun 2010

Sanofi-aventis reports new 1-year data from teriflunomide Phase II study for relapsing multiple sclerosis

Sanofi-aventis reported today new one-year data from a Phase II study with teriflunomide, a novel oral disease modifier being investigated for the treatment of relapsing multiple sclerosis (RMS). Study results demonstrated an improvement in outcomes, with a consistent safety profile with the data from a previous Phase II monotherapy study, in patients treated with interferon beta (IFN-[BETA]) - a standard therapy in RMS - and receiving teriflunomide 7mg or 14mg, compared with patients treated with IFN-[BETA] and receiving oral placebo.

7 Jun 2010

AMG 386 demonstrates antitumor activity in Phase 2 trial involving patients with recurrent ovarian cancer

Amgen today announced that AMG 386, combined with paclitaxel, demonstrated antitumor activity in a randomized Phase 2 trial involving 161 patients with recurrent ovarian cancer. The results are being presented for the first time in an oral presentation at the 2010 American Society of Clinical Oncology Annual Meeting.

7 Jun 2010

Genta reports combined data from Genasense Phase 3 trials for advanced melanoma

Genta Incorporated announced today the presentation of combined data on early endpoints from the Company's randomized Phase 3 trials of Genasense® (oblimersen sodium) Injection plus chemotherapy in patients with advanced melanoma. The presentation included a "pooled analysis" that assessed combined efficacy results for the endpoints of overall response and progression-free survival from both studies. The data were presented today at the 2010 annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL.

7 Jun 2010

Strained relationship with parents following stroke increases depression in daughters: Study

Adult daughters caring for a parent recovering from stroke are more prone to depression than sons, Marina Bastawrous today told the Canadian Stroke Congress, co-hosted by the Canadian Stroke Network, the Heart and Stroke Foundation, and the Canadian Stroke Consortium.

7 Jun 2010

TransMedia to publicize Protectus Automatic, Self-Sheathing Safety Syringe

Protectus Medical Devices, Inc. has retained TransMedia Group to publicize the first automatic, self-sheathing syringe designed to eliminate accidental needle stick injuries that claim the lives of medical professionals and force the industry to spend billions of dollars testing and treating victims for blood borne diseases.

7 Jun 2010

PharmaTelevision offers biopharma companies opportunity to reach key decision makers in financial sector

PharmaTelevision today announced that it is offering pharma and biotech companies the opportunity to reach key decision makers in the financial sector. To celebrate their new relationship with Reuters Insider, PharmaTelevision is offering companies an opportunity to film, host and promote their financial or corporate messages between 21-25 June 2010.

7 Jun 2010

Bevacizumab extends progression-free survival in women with advanced ovarian cancer

Newly reported results from a major clinical trial show that adding bevacizumab (Avastin) to standard frontline chemotherapy for women with advanced ovarian cancer and then continuing a maintenance dose of the drug afterwards significantly extends progression-free survival. Women receiving the new treatment regimen saw no worsening of their disease for 14.1 months, compared to 10.3 months for women receiving standard therapy.

7 Jun 2010

Medical News

O2h signs agreement to provide discovery services to Karyopharm Therapeutics

Merck Serono reports long-term follow-up data of cilengitide Phase II study for recurrent glioblastoma

KMI receives $2.8M grant to support delivery of teletherapy service to stroke survivors in rural areas

Managing Myeloma launches MTR tool to help practitioners treat patients with multiple myeloma

Simcere Pharmaceutical to increase stake in Jilin Boda

Data shows VB-201 controls inflammatory responses associated with autoimmune diseases, atherosclerosis

Adeona completes 50% enrollment in Part 2 CopperProof-2 study of oral zinc cysteine for Alzheimer's Disease

Immersion signs non-exclusive, worldwide license agreement with Simbionix USA

GSK submits BENLYSTA MAA for systemic lupus erythematosus

Pharmacoeconomic methods influence only 13% of hospital formulary system decisions: Survey

Cytheris completes €12 million Series D financing

Millennium reports on data of VELCADE for multiple myeloma from 2010 ASCO oral presentations

ASHP honors First DataBank pharmacist with the title of Fellow for excellence in pharmacy practice

Sanofi-aventis reports new 1-year data from teriflunomide Phase II study for relapsing multiple sclerosis

AMG 386 demonstrates antitumor activity in Phase 2 trial involving patients with recurrent ovarian cancer

Genta reports combined data from Genasense Phase 3 trials for advanced melanoma

Strained relationship with parents following stroke increases depression in daughters: Study

TransMedia to publicize Protectus Automatic, Self-Sheathing Safety Syringe

PharmaTelevision offers biopharma companies opportunity to reach key decision makers in financial sector

Bevacizumab extends progression-free survival in women with advanced ovarian cancer

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Shaping the future of lab automation through AI and robotics

Latest News